Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Tegavivint
Melanoma
Children's Oncology GroupP1/2CC (41)
Vodudeutentan Sodium
Melanoma
ENB Therapeutics, IncP1/2CC (41)
XP-102
Melanoma
Xynomic Pharmaceuticals, Inc.P1/2CC (41)
Zovostotug
Melanoma
OncoResponse, Inc.P1/2CC (41)
5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE
Melanoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (40)
bat4706
Melanoma
Bio-Thera SolutionsP1CC (40)
cft1946
Melanoma
C4 Therapeutics, Inc.P1CC (40)
Ganciclovir
Melanoma
Gene Surgery LLCP1CC (40)
gme751
Melanoma
SandozP1CC (40)
Stimotimagene Copolymerplasmid
Melanoma
Gene Surgery LLCP1CC (40)
Au-Tmp
Melanoma
West China HospitalP1C (39)
Autologous Monocyte-Derived Lysate Pulsed Dendritic Cells
Melanoma
PrimeVax Immuno-Oncology Inc.P1C (39)
bt02
Melanoma
Biotroy TherapeuticsP1C (39)
Cytokine-Induced Memory-Like Natural Killer Cells
Melanoma
Washington University School of MedicineP1C (39)
Dengue Virus-1 #45Az5
Melanoma
PrimeVax Immuno-Oncology Inc.P1C (39)
Fermented Wheat Germ Extract
Melanoma
University of California, DavisP1C (39)
Hs-It101
Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.P1C (39)
Ipn 60090
Melanoma
M.D. Anderson Cancer CenterP1C (39)
Izuralimab
Melanoma
University of California, San FranciscoP1C (39)
Ny-Eso-1 Tcr Redirected Autologous T Cell Product
Melanoma
Centre Hospitalier Universitaire VaudoisP1C (39)
PRT1419
Melanoma
Prelude TherapeuticsP1C (39)
Sitagliptin
Melanoma
Fernando Maciel BarbosaP1C (39)
Cbl-0137 Free Base
Melanoma
Fox Chase Cancer CenterEarly P1C (38)
Acc-1898
Melanoma
AccSalus Biosciences, Inc.P1C (37)
ai-061
Melanoma
OncoC4, Inc.P1C (37)
Alpha-Type-1 Polarized Dendritic Cells
Melanoma
Roswell Park Cancer InstituteP2C (37)
Autologous Cd3+ Enriched T Lymphocytes Obtained From Peripheral Blood Mononuclear Cells (Pbmcs) By Apheresis. The Cells Are Transduced With A Self-Inactivating, Non-Replicating Lentiviral Vector Encoding An Enhanced-Affinity T Cell Receptor (Tcr) Targeting The Hla-A*02:01-Restricted Mage-A4 Peptide (Gvydgrehtv) Alongside The Cd8 Alpha (Cd8?) Co-Receptor. The Expressed Transgene Comprises The Coding Sequence For The Cd8? Co-Receptor, Separated By A Foot-And-Mouth Disease Virus 2A Self-Cleaving Peptide Sequence From The Coding Sequence Of The Mage-A4 T-Cell Receptor Alpha And Beta Chains That Are Separated From Each Other By A Porcine Teschovirus-1 2A Self-Cleaving Peptide Sequence, Under Control Of The Human Elongation Factor 1 Alpha (Ef-1?) Promoter. The Construct Is Flanked By 5' And 3' Long Terminal Repeats (Ltrs) And Also Contains A Trna Primer Binding Site, A ? Packaging Signal, A Truncated Gag, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt) Sequence 5' To The Transgene, And A Polypurine Tract (Ppt) 3' To The Transgene. The Vector Is Pseudotyped With The Vesicular Stomatitis Virus (Vsv) G Envelope Glycoprotein. The Cd3+ T Lymphocytes Are Purified And Activated Using Anti-Cd3/Anti-Cd28 Monoclonal Antibody Coated Magnetic Beads. The Cells Are Then Cultured In Media Containing Interleukin 2 (Il-2), Human Ab Serum And A Protein Kinase B (Akt Inhibitor). The Cells Are Cd3+ (> 80%), Express The High Affinity Mage-A4 Specific Tcr And Cd8? Co-Receptor (Cd8? +Tcr+; >16%) And Are Cytotoxic To Mage-A4 Expressing Tumor Cells
Melanoma
USWM CT, LLCP1C (37)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
Melanoma
USWM CT, LLCP1C (37)
Autologous Total Tumor Mrna Loaded Dotap Liposome Vaccine
Melanoma
University of FloridaP1C (37)
b7-h3 car t cells
Melanoma
St. Jude Children's Research HospitalP1C (37)
ba1302
Melanoma
Shandong Boan Biotechnology Co., LtdP1C (37)
Bdc-3042
Melanoma
Bolt Biotherapeutics, Inc.P1C (37)
Belvarafenib
Melanoma
Genentech, Inc.P1C (37)
bi 3810944
Melanoma
Boehringer IngelheimP1C (37)
bi 765063
Melanoma
Boehringer IngelheimP1C (37)
bi 770371
Melanoma
Boehringer IngelheimP1C (37)
bmc128
Melanoma
Biomica Ltd.P1C (37)
Claturafenib
Melanoma
PfizerP1C (37)
Dcc-3084
Melanoma
Deciphera Pharmaceuticals, LLCP1C (37)
Definity
Melanoma
Sunnybrook Health Sciences CentreP1C (37)
dky709
Melanoma
Novartis PharmaceuticalsP1C (37)
Dp Cd8 Til
Melanoma
AgonOx, Inc.P1C (37)
dxc014
Melanoma
Hangzhou DAC Biotechnology Co., Ltd.P1C (37)
Emunkitug
Melanoma
HiFiBiO TherapeuticsP1C (37)
Exarafenib
Melanoma
Pierre Fabre MedicamentP1C (37)
Ezabenlimab
Melanoma
Boehringer IngelheimP1C (37)
Fludeoxyglucose
Melanoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP1C (37)
Furosemide
Melanoma
M.D. Anderson Cancer CenterP1C (37)
hfb200603
Melanoma
HiFiBiO TherapeuticsP1C (37)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
Melanoma
Genentech, Inc.P1C (37)
Showing 301 to 350 of 435 assets
PreviousPage 7 of 9Next